Zambrano, Laura D.Newhams, Margaret M.Olson, Samantha M.Halasa, Natasha B.Price, Ashley M.Boom, Julie A.Sahni, Leila C.Kamidani, SatoshiTarquinio, Keiko M.Maddux, Aline B.Heidemann, Sabrina M.Bhumbra, Samina S.Bline, Katherine E.Nofziger, Ryan A.Hobbs, Charlotte V.Bradford, Tamara T.Cvijanovich , Natalie Z.Irby, KatherineMack, Elizabeth H.Cullimore, Melissa L.Pannaraj, Pia S.Kong, MicheleWalker, Tracie C.Gertz, Shira J.Michelson, Kelly N.Cameron, Melissa A.Chiotos, KathleenMaamari, MiaSchuster, Jennifer E.Orzel, Amber O.Patel, Manish M.Campbell, Angela P.Randolph, Adrienne G.Overcoming COVID-19 Investigators2024-06-212024-06-212022-01-14Zambrano, L. D. (2022). Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years—United States, July–December 2021. MMWR. Morbidity and Mortality Weekly Report, 71. https://doi.org/10.15585/mmwr.mm7102e1https://hdl.handle.net/1805/41748en-USPublisher Policymultisystem inflammatory syndrome in children (MIS-C)SARS-CoV-2BNT162b2 vaccineArticle